FDA issues guidance to increase drug safety data for pregnant women
The Food and Drug Administration yesterday published draft guidance to promote clinical studies to increase drug safety information for pregnant and nursing women and their providers. One provides recommendations to facilitate studies to inform drug labeling for breastfeeding women. The other includes recommendations on how to design studies to assess pregnancy outcomes in women taking FDA-regulated drugs and biological products during pregnancy. FDA said the recommendations are consistent with those of the created by the 21st Century Cures Act to identify and report on drug safety research and knowledge gaps for pregnant and nursing women. The agency will accept comments on the draft guidance through July 8.
Related News Articles
Headline
The American College of Obstetricians and Gynecologists April 17 released guidance recommending a new approach to prenatal care delivery. The guidance calls…
Headline
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at…
Headline
The National Institutes of Health April 7 released a study that found twins — smaller at birth on average than singletons — develop slower in early pregnancy…
Headline
A National Institutes of Health study published April 2 found that blood pressure patterns observed during the first half of pregnancy can determine a woman's…
Headline
The U.S. District Court for the Eastern District of Texas March 31 ruled that the Food and Drug Administration does not have the authority to regulate…
Headline
As part of the AHA's Patient Safety Initiative, a dedicated webpage features case studies showing how hospitals and health systems across the nation are…